In addition, a paired analysis of NSCLC primary and metastatic sites observed a nonsignificant trend toward increased prevalence of class I HLA LOH in metastatic sites (prevalence in brain metastasis versus primary sites, 43% vs 27%), suggesting an association with more aggressive disease 7 .
← all excerpts
Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities.
1
—
—